HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

ERCC1 and RRM1: ready for prime time?

Abstract
The quest for markers of sensitivity to cytotoxic agents has been ongoing for decades. In non-small-cell lung cancer, platinum compounds represent the cornerstone of systemic therapy. They target DNA and induce damage that cancer cells struggle to overcome. Somatic excision repair cross-complementing rodent repair deficiency, complementation group 1 (ERCC1), and ribonucleotide reductase M1 (RRM1) expression levels have been extensively explored as markers of DNA repair capacity in tumor cells. Although low ERCC1 and/or RRM1 expression is generally associated with sensitivity to platinum, the results published in retrospective and prospective studies are not always consistent. Against this background, we will examine in this review the function of these two biomarkers as well as the tools available for their assessment and the associated technical issues. Their prognostic and predictive values will be summarized and considered in terms of customizing systemic therapy according to biomarker (ERCC1 and RRM1) expression levels. We will also discuss why the use of both markers should at this point be restricted to clinical research and underline that functional readouts of DNA repair will help boost future strategies for biomarker discovery in the field.
AuthorsBenjamin Besse, Ken A Olaussen, Jean-Charles Soria
JournalJournal of clinical oncology : official journal of the American Society of Clinical Oncology (J Clin Oncol) Vol. 31 Issue 8 Pg. 1050-60 (Mar 10 2013) ISSN: 1527-7755 [Electronic] United States
PMID23401439 (Publication Type: Journal Article, Review)
Chemical References
  • Antineoplastic Agents
  • Biomarkers, Tumor
  • DNA-Binding Proteins
  • Platinum Compounds
  • Tumor Suppressor Proteins
  • RRM1 protein, human
  • Ribonucleoside Diphosphate Reductase
  • ERCC1 protein, human
  • Endonucleases
Topics
  • Animals
  • Antineoplastic Agents (therapeutic use)
  • Biomarkers, Tumor (genetics)
  • Carcinoma, Non-Small-Cell Lung (genetics, pathology, therapy)
  • DNA Repair
  • DNA-Binding Proteins (genetics, physiology)
  • Disease Progression
  • Endonucleases (genetics, physiology)
  • Gene Expression Regulation, Neoplastic (drug effects)
  • Humans
  • Lung Neoplasms (genetics, pathology, therapy)
  • Platinum Compounds (therapeutic use)
  • Precision Medicine
  • Predictive Value of Tests
  • Prognosis
  • Ribonucleoside Diphosphate Reductase
  • Tumor Suppressor Proteins (genetics, physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: